



Cisplatin, Fluorouracil in Bolus Injection, and Leucovorin in First-Line Therapy for Advanced Gastric Cancer as an Alternative to Protocols With Infusional Fluorouracil

Rafael C. Coelho, MD, MSc^{1,2}; Pedro D.P. Abreu, MD¹; Mariana R. Monteiro, MD¹; Ana Paula Stramosk, MD¹; Alvaro Henrique I. Garces, MD¹; Andreia Cristina Melo, MD, PhD¹; Marcia S. Graudenz, MD, PhD^{2,3}; and Carlos Jose C. Andrade, MD¹

PURPOSE Gastric cancer (GC) is the fourth most common cancer and the second leading cause of cancer death worldwide. Platinum agents and fluoropyrimidines are the main compounds used in the first-line setting for advanced GC. Given the activity of fluorouracil (FU) bolus, the PFL protocol, a chemotherapy regimen combining cisplatin, FU bolus, and leucovorin, was incorporated at the Brazilian National Cancer Institute, because this schedule does not require hospitalization or infusion pumps. This study aims to evaluate the outcomes of PFL in the first-line setting for patients with advanced GC.

MATERIALS AND METHODS This was a retrospective cohort study evaluating patients with advanced GC treated in the first-line setting with cisplatin 80 mg/m² on day 1 and FU bolus 400 mg/m² plus leucovorin 20 mg/m² on days 1, 8, 15, and 22 every 4 weeks, from January 2008 to December 2014.

RESULTS A total of 109 patients were enrolled. The median number of cycles received per patient was four (one to 11). Complete responses were achieved in 6.4% and partial responses in 14.7%. Median progression-free survival was 6.3 months (95% CI, 5.08 to 7.58 months) and median overall survival was 8.3 months (95% CI, 6.79 to 9.87 months). Thirty-four (31.2%) patients were alive in 1 year. Grade 3 and 4 adverse events were experienced by 26.6% and 3.7% of patients, respectively, with dose reduction necessary in 9.1%.

CONCLUSION PFL is active in advanced GC and could be an alternative for FU continuous infusion protocols in institutions with limited resources and/or low budget, which is the reality in many nations all over the world.

J Global Oncol. © 2019 by American Society of Clinical Oncology

Licensed under the Creative Commons Attribution 4.0 License

INTRODUCTION

Gastric cancer (GC) is a major health problem, and it is the fourth most common cancer and the second leading cause of cancer death worldwide. More than 950,000 new cases are diagnosed every year. It was estimated that 720,000 patients died as a result of gastric cancer in 2012.^{1,2} In Brazil, 13,540 new cases of GC are expected for men and 7,750 for women in 2018, being the fourth most incident tumor type in men and the sixth in women.³

Patients with GC have a poor prognosis, with median survival of around 12 months when treated with cytotoxic chemotherapy with or without target therapies.⁴ First-line treatment of advanced GC is historically based on combinations of platinum compounds and fluoropyrimidines. These drugs can also be associated with taxanes and anthracyclines; for human epidermal growth factor receptor 2–positive tumors, trastuzumab combined with fluoropyrimidine and platinum-based chemotherapy is considered the standard of care.⁴

Fluorouracil (FU) may be administered by intravenous bolus or as a continuous infusion, and each protocol

influences its pharmacological behavior and cytotoxic effects involving RNA and DNA synthesis.⁵ FU can be incorporated into nuclear RNA in the form of fluorouridine 5′-triphosphate,⁶ and its impact on DNA synthesis is mainly through the inhibition of thymidylate synthase by 5-fluoro-2′ deoxyuridine-5′ monophosphate⁷ and, to a lesser extent, through its incorporation into DNA.⁸ Sobrero et al⁹ highlighted the role of decreased thymidylate synthase inhibition in the mechanism of resistance to infusional FU, in contrast to the role of decreased incorporation of FU into RNA in the mechanism of resistance to FU bolus.

In vivo pharmacokinetic comparison of bolus versus continuous infusion FU administration shows that the latter results in more constant plasmatic drug levels.¹⁰ Given that the cytotoxicity of FU is optimal during cell division, the constant drug levels achieved by continuous infusion ensure that a larger number of cells are exposed to FU during the cell cycle.¹¹ The superiority of continuous infusion FU administration when compared with bolus infusion in the treatment of metastatic colorectal cancer is highlighted in

Author affiliations and support information (if applicable) appear at the end of this article.

Accepted on November 20, 2018 and published at ascopubs.org/journal/jgo on January 22, 2019; DOI <https://doi.org/10.1200/JGO.18.00176>

CONTEXT

Is it possible to treat patients with advanced gastric cancer (GC) with bolus fluorouracil (FU) infusion in the first-line setting? Treatment with a regimen containing cisplatin, bolus FU, and leucovorin (PFL) was demonstrated to be active and have a favorable toxicity profile in patients treated in the first-line setting of advanced GC.

PFL demonstrated an overall survival of 8.3 months, in line with main phase III randomized trials.

PFL protocol could be an alternative for treatment of advanced GC in institutions with limited resources and/or budget without access to infusion pumps and/or capecitabine, which can be the reality in many nations all over the world.

a meta-analysis of seven randomized studies on the basis of data from 1,219 individual patients.¹² The continuous infusion resulted in a higher response rate (22% v 14%; $P = .002$) and a small but significant survival difference (12.1 v 11.3 months; $P = .039$). None of the individual trials included in the meta-analysis had reported a significant survival benefit.¹² Regarding gastric cancer, there is no trial comparing these two administration modes directly.

Given the activity of FU bolus administration shown in many preclinical and clinical studies, similar outcomes when compared with infusional protocols,⁵⁻¹² and the convenient schedule without the need of hospitalization or infusion pumps, PFL protocol, a chemotherapy regimen combining cisplatin (CDDP), FU in bolus infusion, and leucovorin (LV), was incorporated at the Brazilian National Cancer Institute (INCA). This study aims to evaluate the outcomes of the PFL protocol for advanced GC.

MATERIALS AND METHODS

All patients included in this study were treated, after obtaining their consent, from January 2008 to December 2014 at the INCA (Rio de Janeiro, Brazil). This study was approved by the INCA's Ethics in Human Research Committee and conducted in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines.

This retrospective cohort study evaluated patients with advanced GC defined as those with metastatic or unresectable disease. Patients were identified through an internal database. Advanced disease had to be documented by imaging and treated in the first-line setting with CDDP 80 mg/m² on day 1; FU 400 mg/m² on days 1, 8, 15, and 22; and LV 20 mg/m² on days 1, 8, 15, and 22 every 4 weeks (PFL regimen). CDDP was diluted in 400 ml of normal saline and mannitol 20% 100 ml, being infused over 60 minutes, followed by LV diluted in 100 ml of 5% glucose solution over 15 minutes and FU in bolus diluted in 100 ml of normal saline after LV. Hydration and electrolytes replacement were performed before and after CDDP infusion.

Clinical data were collected from medical records and included demographics, stage, histology, Eastern Cooperative Oncology Group performance status, clinical and imaging response assessment, tumor characteristics,

adverse events, and prior neoadjuvant and adjuvant treatments. Response to treatment was assessed using clinical and radiologic criteria as follows: complete response, partial response, progressive disease (PD), and stable disease (SD). The radiologic evaluation was based on the Response Evaluation Criteria in Solid Tumors, version 1.1,¹³ with a frequency determined by the assistant physician. Evaluation of drug toxicities was standardized according to the National Cancer Institute Common Toxicity Criteria, version 3.0.¹⁴ Patients receiving the PFL regimen for second-line advanced GC, neoadjuvant and/or adjuvant setting, were excluded, as well as patients with another primary cancer (except nonmelanoma skin cancer) and patients for whom data were not available in medical charts.

Although this study was not designed for a cost-effectiveness analysis, an estimated budget of each of the most common first-line chemotherapeutic regimens per cycle was performed considering only the cost of the drugs, hospitalization, and/or devices. The standard body surface for estimating treatment costs was 1.85 m². The costs of drugs, devices, and procedures are those currently applied to the Brazilian Public Health System. The cost of antiemetic drugs was \$5.00 in regimens without CDDP and \$7.00 with it. We did not have neurokinin inhibitors at our disposal, which could increase the costs of antiemetic drugs substantially. Protocols with the need for prolonged infusion had the cost of hospital stay per day (US\$95.99/d) or infusion pump device (48 hours, US\$39.19 and 96 hours, US\$39.35) added. Those who received the treatment through an infusion pump had the catheter implantation costs of US\$218.18 added to the value described in Table 1. To calculate the costs in US dollars, the conversion rate of US\$1.00 = R\$3.75 was applied.

Overall survival (OS) was estimated from the time of the first day of infusion of the PFL regimen until death or, for living patients, the last available follow-up. PFS was measured from the starting date of the PFL treatment to either first disease progression or death or the date of the last contact for patients who are alive and progression free, in both cases using the Kaplan-Meier method. All descriptive analyses were performed with SPSS Statistics for Windows, version 18.0 (SPSS, Chicago, IL).

TABLE 1. Clinical Studies Evaluating Chemotherapy in First-Line Setting of Advanced Gastric Cancer

First Author, Type of Study	No. of Patients	Treatment Regimen	Toxicities	Response Rate (%)	PFS or TTP (months)	OS (months)	Treatment Costs per Cycle (US\$)
Coelho, this retrospective study	PFL: 109	CDDP (80 mg/m ²) day 1; FU (400 mg/m ²) days 1, 8, 15, 22; and LV (20 mg/m ²) days 1, 8, 15, and 22 every 4 weeks	Grade 3 and 4 adverse events, 26.6% and 3.7%, respectively. The most common toxicities were nausea 72%, vomiting 50%, fatigue 35%, diarrhea 29%, constipation 12%, stomatitis 11%, and neutropenia 11%.	CR, 6.4 PR, 14.7	PFS, 6.3 (95% CI, 5.08 to 7.58)	8.33 (95% CI, 6.79 to 9.87)	114.13
Van Cutsem ¹⁵ Phase III trial	DCF: 221; CF: 224	DCF: docetaxel 75 mg/m ² and CDDP 75 mg/m ² (day 1) plus FU 750 mg/m ² /d (days 1-5) every 3 weeks; CF: CDDP 100 mg/m ² (day 1) plus FU 1,000 mg/m ² /d (days 1 to 5) every 4 weeks	Grade 3 or 4 treatment-related adverse events occurred in 69% (DCF) v 59% (CF). Frequent grade 3 or 4 toxicities for DCF v CF were: neutropenia (82% v 57%), stomatitis (21% v 27%), diarrhea (19% v 8%), lethargy (19% v 14%). Complicated neutropenia was more frequent with DCF than CF (29% v 12%).	DCF: CR, 2; PR, 35; CF: CR, 1; PR, 24	Primary end point, TTP DCF: 5.6; CF: 3.7 (HR, 1.47; 95% CI, 1.19 to 1.82; log-rank <i>P</i> < .001; risk reduction 32%)	DCF: 9.2; CF: 8.6 (HR, 1.29; 95% CI, 1.0 to 1.6; log-rank <i>P</i> = .02; risk reduction 23%)	DCF: 342.94 IP, 618.13 IH. CF: 135.99 IP, 411.19 IH
Cunningham ¹⁶ Phase III noninferiority trial	ECF: 263; ECX: 250; EOF: 245; EOX: 244	ECF: epirubicin 50 mg/m ² plus CDDP 60 mg/m ² plus FU 200 mg/m ² once daily every 3 weeks. ECX: epirubicin 50 mg/m ² plus CDDP 60 mg/m ² plus capecitabine 1,250 mg/m ² /d every 3 weeks. EOF: epirubicin 50 mg/m ² plus oxaliplatin 130 mg/m ² plus FU 200 mg/m ² once daily every 3 weeks. EOX: epirubicin 50 mg/m ² plus oxaliplatin 130 mg/m ² plus capecitabine 1,250 mg/m ² /d every 3 weeks.	Toxic effects of capecitabine and fluorouracil were similar. As compared with cisplatin, oxaliplatin was associated with lower incidences of grade 3 or 4 neutropenia, alopecia, renal toxicity, and thromboembolism but with slightly higher incidences of grade 3 or 4 diarrhea and neuropathy.	ECF: CR, 4.1; PR, 36.6. ECX: CR, 4.2; PR, 42.2. EOF: CR, 2.6; PR, 39.8. EOX: CR, 3.9; PR, 44	ECF: PFS, 6.2. ECX: PFS, 6.7. EOF: PFS, 6.5. EOX: PFS, 7	Primary end point ECF: 9.9; ECX: 9.9; EOF: 9.3; EOX: 11.2	ECF: 490.46; ECX: 227.06; EOF: 566.8; EOX: 303.20

(Continued on following page)

TABLE 1. Clinical Studies Evaluating Chemotherapy in First-Line Setting of Advanced Gastric Cancer (Continued)

First Author, Type of Study	No. of Patients	Treatment Regimen	Toxicities	Response Rate (%)	PFS or TTP (months)	OS (months)	Treatment Costs per Cycle (US\$)
Al-Batran ¹⁷ Phase III trial	FLP: 108; FLO: 112	FLP: FU 2,000 mg/m ² via 24-hour infusion, LV 200 mg/m ² once weekly, and CDDP 50 mg/m ² every 2 weeks. FLO: FU 2,600 mg/m ² via 24-hour infusion, LV 200 mg/m ² , and oxaliplatin 85 mg/m ² every 2 weeks	FLO was associated with significantly less (any grade) anemia (54% v 72%), nausea (53% v 70%), vomiting (31% v 52%), alopecia (22% v 39%), fatigue (19% v 34%), renal toxicity (11% v 34%), thromboembolic events (0.9% v 7.8%), and serious adverse events related to the treatment (9% v 19%). FLP was associated with significantly less peripheral neuropathy (22% v 63%)	FLP: 24.5; FLO: 34.8	Primary end point, PFS; FLO v FLP: 5.8 v 3.9, respectively; <i>P</i> = .077	FLP: 8.8; FLO: 10.7	FLP: 285.60; FLO: 218.25
Al-Batran ¹⁸ Phase II trial	FLOT: 54	Oxaliplatin 85 mg/m ² , LV 200 mg/m ² , and docetaxel 50 mg/m ² , each as a 1- to 2-hour infusion followed by FU 2,600 mg/m ² as a 24-hour continuous infusion every 2 weeks	Frequent (> 10%) grade 3 or 4 toxic effects included neutropenia in 26 (48.1%), leukopenia in 15 (27.8%), diarrhea in eight (14.8%), and fatigue in six (11.1%) patients. Complicated neutropenia was observed in two (3.8%) patients.	Primary end point (n = 52) CR, 3.8; PR, 53.8	PFS, 5.2 (95% CI, 4.4 to 8.4)	11.1 (95% CI, 9.3 to 17.3)	FLOT: 342.91 IH
Kang ¹⁹ Phase III noninferiority trial	CX: 160; CF: 156	CX: CDDP (80 mg/m ² , day 1) plus oral capecitabine (2,000 mg/m ² /d, days 1-14) CF: CDDP (80 mg/m ² , day 1) plus FU (800 mg/m ² /d by continuous infusion, days 1-5) every 3 weeks	The most common treatment-related grade 3 or 4 adverse events in patients receiving CX v CF were as follows: neutropenia (16% v 19%), vomiting (7% v 8%), and stomatitis (2% v 6%).	CX: RR, 46 (95 CI, 38 to 55); CF: RR, 32 (95 CI, 24 to 41); OR, 1.80 (95 CI, 1.11 to 2.94); <i>P</i> = .020	Primary end point PFS XP (n = 139), 5.6; FP (n = 137), 5.0 (HR, 0.81; 95% CI, 0.63 to 1.04; <i>P</i> < .001; noninferiority margin of 1.25)	NA	CX: 143.99; CF: 110.12 IP, 411.19 IH
Ajani ²⁰ Phase III trial	CF: 526; CS1: 527	CF: FU 1,000 mg/m ² /24 hours for 120 hours and CDDP at 100 mg/m ² IV on day 1, repeated every 28 days CS1: S-1 at 50 mg/m ² divided in two daily doses for 21 days and CDDP 75 mg/m ² on day 1 every 4 weeks	Significant safety advantages were observed in the CS1 arm compared with the CF arm for the rates of grade 3 or 4 neutropenia (32.3% v 63.6%), complicated neutropenia (5.0% v 14.4%), stomatitis (1.3% v 13.6%), hypokalemia (3.6% v 10.8%), and treatment-related deaths (2.5% v 4.9%; <i>P</i> < .05).	CF (n = 402): RR, 31.9; CS1 (n = 385): RR, 29.1 (Fisher's exact test <i>P</i> = .40)	PFS CS1 (n = 521): 4.8; CF (n = 508): 5.5 (HR, 0.99; 95% CI, 0.86 to 1.14)	Primary end point CS1 (n = 521): 8.6; CF (n = 508): 7.9 (HR, 0.92; 95% CI, 0.80 to 1.05; <i>P</i> = .20).	CF: 136.02 IP, 397.87 IH; CS1: S-1 is not available in Brazilian Public Health System

(Continued on following page)

TABLE 1. Clinical Studies Evaluating Chemotherapy in First-Line Setting of Advanced Gastric Cancer (Continued)

First Author, Type of Study	No. of Patients	Treatment Regimen	Toxicities	Response Rate (%)	PFS or TTP (months)	OS (months)	Treatment Costs per Cycle (US\$)
Yun ²¹ Phase II trial	CX: 45; ECX: 44	CX: CDDP 75 mg/m ² on day 1 and capecitabine 2,000 mg/m ² /d on days 1-14. ECX: epirubicin 50 mg/m ² plus CX every 3 weeks	There was no relevant difference in the occurrence of overall grade 3 or 4 toxicities between the CX and ECX arms (80% v 78%, respectively; <i>P</i> = .516). However, none in the CX and 12% in the ECX arm discontinued treatment because of toxicity.	CX: 38; ECX: 37	Primary end point, PFS CX: 6.4; ECX: 6.5 (<i>P</i> = .863)	NA	CX: 143.99; ECX: 227.06
Bang ²² Phase III trial	CX or CF plus trastuzumab: 298; CX or CF alone: 296	CX: CDDP 80 mg/m ² on day 1 was administered by IV infusion; capecitabine 2,000 mg/m ² /d for 14 days followed by a 1-week rest. CF: FU 800 mg/m ² /d was administered by continuous IV infusion on days 1-5 of each cycle. Chemotherapy was administered every 3 weeks for six cycles. Trastuzumab was administered by IV infusion at a dose of 8 mg/kg on day 1 of the first cycle, followed by 6 mg/kg every 3 weeks until PD, unacceptable toxicity, or withdrawal of consent.	The most common adverse events in both groups were nausea (trastuzumab plus chemotherapy, 197 [67%] v chemotherapy alone, 184 [63%]), vomiting (147 [50%] v 134 [46%]), and neutropenia (157 [53%] v 165 [57%]). Rates of overall grade 3 or 4 adverse events (201 [68%] v 198 [68%]) and cardiac adverse events (17 [6%] v 18 [6%]) did not differ between groups.	CXT or CFT: CR, 5; PR, 42; CX or CF: CR, 2; PR, 32; OR for PR, 1.52 (1.09 to 2.14; χ^2 test <i>P</i> = .0145)	PFS, CXT or CFT: 6.7; CX or CF: 5.55 (HR, 0.71; 95% CI, 0.59-0.86) <i>P</i> < .001	Primary end point CXT or CFT: 16; CX or CF: 11.8 (HR, 0.65; 95% CI, 0.51 to 0.83)	CX: 143.99; CF: 110.12 IP, 411.19 IH; trastuzumab is not available in Brazilian Public Health System for advanced gastric cancer treatment

Abbreviations: CDDP, cisplatin; CR, complete response; FU, fluorouracil; HR, hazard ratio; IH, patients receiving treatment in hospital; IP, patients receiving treatment by infusion pump without need of hospital admission; IV, intravenous; LV, leucovorin; NA, not applicable; OR, odds ratio; OS, overall survival; PD, progressive disease; PFS, progression-free survival; PR, partial response; RR, response rate; SD, stable disease; S-1, tegafur/gimeracil/oteracil; TTP, time to progression.

RESULTS

One hundred nine patients were eligible for this study (Fig 1). Tumor characteristics at diagnosis and epidemiologic data are listed in Table 2.

The median number of cycles of treatment received per patient was four (one to 11). The median interval between radiologic evaluations was 4 months. Seven patients (6.4%) achieved complete response, 16 (14.7%) had partial response, 16 (14.7%) SD, and 54 (49.5%) PD. Sixteen patients (14.7%) had no response assessment described in their medical records.

The median PFS was 6.3 months (95% CI, 5.08 to 7.58 months), and median OS was 8.3 months (95% CI, 6.79 to 9.87 months; Fig 2). Thirty-four (31.2%) patients were alive after 1 year and eight patients (7.3%) after 2 years.

No differences were found in PFS and OS between patients with nonmetastatic and metastatic GC at diagnosis. Table 1 lists the outcomes of the PFL regimen and compares it with important phase II and III clinical trials evaluating the role of platinum compounds and FU in advanced GC.

The most common toxicities in all grades were nausea (72%), vomiting (50%), fatigue (35%), diarrhea (29%), constipation (12%), stomatitis (11%), and neutropenia (11%). Of all adverse events, grade 3 and 4 corresponded to 26.6% and 3.7%, respectively. Three patients had grade 4 neutropenia, one had grade 4 febrile neutropenia, and one died as a result of dehydration from diarrhea. Dose reduction was necessary in 9.1% of cases.

Three patients were re-exposed to the PFL regimen after progressive disease, and only 27 patients (24.8%) received




FIG 1. Flowchart of patients eligible for the study. PFL, cisplatin, fluorouracil bolus, and leucovorin.

second-line treatment. Three were treated with an oxaliplatin-based regimen and 18 with irinotecan single agent.

DISCUSSION

GC is a major concern in many countries around the world, especially in developing nations; its burden remains high in Asia, Latin America, and Central and Eastern Europe.¹⁻³ Low educational status, negligence, limited access to the public health system, social disparities, scarce resources, high prevalence of smoking and alcoholism, and dietary habits are important factors influencing this epidemiologic data. Unfortunately, treatment of advanced GC is still an unmet need, and new and effective therapeutic strategies are needed across all lines of therapy.⁴

Chemotherapy is a well-established treatment of advanced GC, improving the quality of life and OS.^{12,15-20,22,23} In this study, survival, response, and toxicity were evaluated in a cohort of patients with GC treated with FU bolus and CDDP in the first-line setting.

In an indirect comparison, patients' outcomes with PFL protocol were similar to those already published in the literature, as shown in Table 1.¹⁵⁻²² The OS was 8.3 months (95% CI, 6.79 to 9.87 months) and PFS 6.3 months (95% CI, 5.08 to 7.58 months). Some explanations for the timeframe proximity of these two outcomes are the low number of patients receiving second-line treatment and the absence of standardization for response assessment.

The response rate was also similar to other trials showing 21.1% of patients with tumor shrinkage after treatment. The proportion of PD as best response was greater than what was previously described in the literature,¹⁵⁻²²

TABLE 2. Baseline and Tumor Characteristics of the Total Study Population (N = 109)

Characteristics	No.	%
Age, years		
Median	54	
Range	24-80	
Sex		
Male	58	53.2
Female	51	46.8
Schooling		
Illiterate	7	6.4
≤ 8 years	63	57.8
> 8 years	39	35.8
Race		
White	77	70.6
Black	10	9.2
Brown	22	20.2
Former/current smoker		
Yes	54	49.5
Former/current drinker		
Yes	17	15.6
Differentiation grade		
Grade 1	3	2.8
Grade 2	31	28.4
Grade 3	70	64.2
Unknown	5	4.6
Performance status		
≤ 1	95	87.2
2	12	11
3	2	1.8
Unresectable disease	21	19.2
Metastatic sites		
Peritoneum	49	45
Lymph nodes	35	32.1
Liver	24	22
Pleura	6	5.5
Lung	3	2.8
Other	59	52.1

reaching 49.5% of patients; nonetheless, this could be related to the absence of standardization in time of imaging and clinical evaluation for response assessment. Therefore, patients without symptoms had their imaging evaluation postponed; despite the likelihood of having objective response or SD, they were considered as nonresponders, taking into consideration that imaging was performed only during the symptomatic phase of PD. This hypothesis is reinforced in this retrospective study because the main end point, OS, is within the range of the three main phase III




FIG 2. Overall survival among patients with advanced gastric cancer treated with palliative cisplatin, fluorouracil bolus, and leucovorin. Overall survival, 8.3 months (95% CI, 6.79 to 9.87 months).

trials evaluating the CDDP and FU combination, which is between 7.9 and 8.6 months.^{15,20}

Toxicities were manageable, and the treatment with PFL was well tolerated. The most common adverse events were nausea and vomiting, but mainly grades 1 and 2. The explanation for the high prevalence of these two toxicities, besides the high dose of CDDP, is that from 2008 to 2011 there were no neurokinin 1 and 5-HT₃ antagonists for vomiting prophylaxis available for patients treated in our institution; the latter was introduced routinely only after 2012. Neutropenia occurred in 13.76% of patients. Some other chemotherapy regimens have shown antitumor activity, but their toxicity profiles can limit their use in this usually frail population.⁴ However, PFL was shown to be feasible and a tolerable treatment for this group of patients.

AFFILIATIONS

¹Instituto Nacional de Câncer (INCA), Rio de Janeiro, Brazil

²Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre, Brazil

³Hospital de Clinicas de Porto Alegre, Porto Alegre, Brazil

CORRESPONDING AUTHOR

Rafael C. Coelho, MD, MSc, Department of Clinical Oncology, Brazilian National Cancer Institute, Praça da Cruz Vermelha, 23 – Centro, Rio de Janeiro/RJ 20230-130, Brazil; e-mail: rccmed@gmail.com.

PRIOR PRESENTATION

The abstract of this article was accepted for online publication only in ASCO 2017.

The concern about adverse events is related to the different toxicities between bolus and infusional FU schemes. A meta-analysis revealed that grade 3 and 4 hematologic toxicity (especially neutropenia) was seven times more common in patients who received bolus infusion ($P < .001$). The risks of severe diarrhea, nausea, vomiting, and stomatitis were not different between the two groups. The risk of developing hand-foot syndrome was lower with FU bolus than with FU continuous infusion (13% and 34%, respectively; $P < .0001$).¹²

In terms of costs per cycle, PFL and combinations with capecitabine may be a cheaper alternative than the majority of other regimens, as described in Table 1. The reduction in costs and time spent in infusion could expand the access to treatment to hospitals with low budget and limited infrastructure.

The retrospective methodology; absence of a strict control in the intervention group; missing data in patient records; lack of standardized chemotherapeutic regimens in neo-adjuvant, adjuvant, and second-line settings; and absence of a standardized schedule for imaging response evaluation are the main limitations in this study. On the other hand, the strongest points of this study are that it is a large cohort evaluating a group of patients with advanced GC receiving only one chemotherapeutic regimen, and it shows the treatment of GC in a real-life setting, outside a clinical trial.

The PFL protocol is feasible and well tolerated, and its outcomes are in line with the main prospective phase III trials that evaluated first-line treatment of advanced GC.¹⁵⁻²² It is necessary to highlight that the main objective of this study was not to directly compare the outcomes of this retrospective cohort with those clinical trials already published. However, PFL could be an alternative for those institutions that lack the resources to offer the standard-of-care protocols, widening treatment access for patients. In conclusion, a chemotherapy protocol combining CDDP, FU in bolus injection, and LV could be an active and feasible alternative for FU continuous infusion protocols in the outpatient setting for low-budget and resource-limited institutions, which is pragmatically the reality of many nations all over the world.

AUTHOR CONTRIBUTIONS

Administrative support: Andreia Cristina Melo, Marcia S. Graudenz

Conception and design: Rafael C. Coelho, Pedro D.P. Abreu, Mariana R. Monteiro, Andreia Cristina Melo, Carlos Jose C. Andrade

Provision of study material or patients: Andreia Cristina Melo, Carlos Jose C. Andrade

Collection and assembly of data: Rafael C. Coelho, Pedro D.P. Abreu, Mariana R. Monteiro, Ana Paula Stramosk, Andreia Cristina Melo

Data analysis and interpretation: Rafael C. Coelho, Pedro D.P. Abreu, Alvaro Henrique I. Garces, Andreia Cristina Melo, Marcia S. Graudenz, Carlos Jose C. Andrade

Manuscript writing: All authors

Final approval of manuscript: All authors

Accountable for all aspects of the work: All authors

AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/site/ifc.

Andreia Cristina Melo

Honoraria: MSD Oncology, Novartis, Bristol-Myers Squibb Brazil

Consulting or Advisory Role: Roche

Speakers' Bureau: Bristol-Myers Squibb Brazil, MSD Oncology

Research Funding: Roche (Inst), MSD Oncology (Inst), Bristol-Myers Squibb Brazil (Inst), Novartis (Inst), Clovis Oncology (Inst)

Travel, Accommodations, Expenses: MSD Oncology

Marcia S. Graudenz

Speakers' Bureau: Genentech

Travel, Accommodations, Expenses: Myriad Genetics

No other potential conflicts of interest were reported.

ACKNOWLEDGMENT

We thank the Brazilian National Cancer Institute research team for their contribution to statistical analysis.

REFERENCES

1. Ferlay J, Soerjomataram I, Dikshit R, et al: Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. *Int J Cancer* 136:E359-E386, 2015
2. Ferro A, Peleteiro B, Malvezzi M, et al: Worldwide trends in gastric cancer mortality (1980-2011), with predictions to 2015, and incidence by subtype. *Eur J Cancer* 50:1330-1344, 2014
3. Estimativa 2018 - Incidência de câncer no Brasil: <http://www1.inca.gov.br/estimativa/2018/estimativa-2018.pdf>
4. Taieb J, Moehler M, Boku N, et al: Evolution of checkpoint inhibitors for the treatment of metastatic gastric cancers: Current status and future perspectives. *Cancer Treat Rev* 66:104-113, 2018
5. El-Khoueiry AB, Lenz H-J: Should continuous infusion 5-fluorouracil become the standard of care in the USA as it is in Europe? *Cancer Invest* 24:50-55, 2006
6. Mandel HG: The target cell determinants of the antitumor actions of 5-FU: does FU incorporation into RNA play a role? *Cancer Treat Rep* 65:63-71, 1981 (suppl 3)
7. Danenberg PV: Thymidylate synthetase - A target enzyme in cancer chemotherapy. *Biochim Biophys Acta* 473:73-92, 1977
8. Danenberg P V, Heidelberger C, Mulkins MA, et al: The incorporation of 5-fluoro-2'-deoxyuridine into DNA of mammalian tumor cells. *Biochem Biophys Res Commun* 102:654-658, 1981
9. Sobrero AF, Aschele C, Bertino JR: Fluorouracil in colorectal cancer--A tale of two drugs: Implications for biochemical modulation. *J Clin Oncol* 15:368-381, 1997
10. Fraile RJ, Baker LH, Buroker TR, et al: Pharmacokinetics of 5-fluorouracil administered orally, by rapid intravenous and by slow infusion. *Cancer Res* 40:2223-2228, 1980
11. Hansen RM: 5-Fluorouracil by protracted venous infusion: A review of recent clinical studies. *Cancer Invest* 9:637-642, 1991
12. Meta-Analysis Group In Cancer, Lévy E, Piedbois P, et al: Toxicity of fluorouracil in patients with advanced colorectal cancer: Effect of administration schedule and prognostic factors. *J Clin Oncol* 16:3537-3541, 1998
13. Therasse P, Arbusk SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. *J Natl Cancer Inst* 92:205-216, 2000
14. National Institute of Cancer: Common Terminology Criteria for Adverse Events (CTCAE). http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcae3.pdf
15. Van Cutsem E, Moiseyenko VM, Tjulandin S, et al: Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: A report of the V325 Study Group. *J Clin Oncol* 24:4991-4997, 2006
16. Cunningham D, Starling N, Rao S, et al: Capecitabine and oxaliplatin for advanced esophagogastric cancer. *N Engl J Med* 358:36-46, 2008
17. Al-Batran S-E, Hartmann JT, Probst S, et al: Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: A study of the Arbeitsgemeinschaft Internistische Onkologie. *J Clin Oncol* 26:1435-1442, 2008
18. Al-Batran S-E, Hartmann JT, Hofheinz R, et al: Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: A phase II trial of the Arbeitsgemeinschaft Internistische Onkologie. *Ann Oncol* 19:1882-1887, 2008
19. Kang Y-K, Kang W-K, Shin D-B, et al: Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: A randomised phase III noninferiority trial. *Ann Oncol* 20:666-673, 2009
20. Ajani JA, Rodriguez W, Bodoky G, et al: Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: The FLAGS trial. *J Clin Oncol* 28:1547-1553, 2010
21. Yun J, Lee J, Park SH, et al: A randomised phase II study of combination chemotherapy with epirubicin, cisplatin and capecitabine (ECX) or cisplatin and capecitabine (CX) in advanced gastric cancer. *Eur J Cancer* 46:885-891, 2010
22. Bang Y-J, Van Cutsem E, Feyereislova A, et al: Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomised controlled trial. *Lancet* 376:687-697, 2010
23. Wagner AD, Syn NL, Moehler M, et al: Chemotherapy for advanced gastric cancer. *Cochrane Database Syst Rev* 8:CD004064, 2017

